Evaluation of the performance of Abbott Panbio™ COVID-19 antigen rapid diagnostic test for the detection of severe acute respiratory syndrome coronavirus 2 at Harar, Eastern Ethiopia
- PMID: 37324158
- PMCID: PMC10266096
- DOI: 10.3389/fmed.2023.1135027
Evaluation of the performance of Abbott Panbio™ COVID-19 antigen rapid diagnostic test for the detection of severe acute respiratory syndrome coronavirus 2 at Harar, Eastern Ethiopia
Abstract
Background: Rapid antigen tests can help in the effective isolation of symptomatic cases and the systematic tracing of close contacts. However, their reliability must be validated before implementing them widely.
Methods: A cross-sectional study was conducted on 236 COVID-19-suspected patients visiting four different health institutions in Harari Regional State, Harar, Eastern Ethiopia, from June to July 2021. Two nasopharyngeal samples were collected and processed by the Panbio™ Ag-RDT kit and qRT-PCR. The collected data were analyzed using SPSS version 25.0.
Results: The Panbio tests had a sensitivity of 77.5% (95% CI: 61.6-89.2%) and a specificity of 98.5% (95% CI: 95.6-99.7%). It also had a positive predictive value of 91.2% (95% CI: 76.9-96.9%), a negative predictive value of 95.5% (95% CI: 92.3-97.4%), and a kappa of 0.81 (95% CI: 0.7-0.9). The test had a sensitivity of 94.4%, 100%, 100%, and 90% in the samples collected from patients within the 1-5 days post-onset of COVID-19 signs and symptoms, of age group ≤18 years old, with cycle threshold values of <20, and with household contact, respectively.
Conclusion: This test can be used as point-of-care testing for the diagnosis of symptomatic patients with short clinical courses and contact with patients in households.
Keywords: Eastern Ethiopia; Harar; Panbio™; RT-PCR; Rapid diagnostic test; SARS-CoV-2; sensitivity; specificity.
Copyright © 2023 Teklemariam, Feleke, Abdurahman, Alemayehu, Demissie, Tufa, Sherefa, Mohammed, Brhane and Bogale.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Evaluation of the Abbott Panbio™ COVID-19 antigen detection rapid diagnostic test among healthcare workers in elderly care.PLoS One. 2023 Feb 24;18(2):e0276244. doi: 10.1371/journal.pone.0276244. eCollection 2023. PLoS One. 2023. PMID: 36827362 Free PMC article.
-
Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients.Clin Microbiol Infect. 2021 Apr;27(4):636.e1-636.e4. doi: 10.1016/j.cmi.2020.12.022. Epub 2021 Jan 6. Clin Microbiol Infect. 2021. PMID: 33421573 Free PMC article.
-
Evaluation of the performance of Panbio™ COVID-19 antigen rapid diagnostic test for the detection of SARS-CoV-2 in suspected patients in Ethiopia.SAGE Open Med. 2022 Jul 14;10:20503121221110079. doi: 10.1177/20503121221110079. eCollection 2022. SAGE Open Med. 2022. PMID: 35860810 Free PMC article.
-
Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care.J Infect. 2021 Mar;82(3):391-398. doi: 10.1016/j.jinf.2021.02.014. Epub 2021 Feb 13. J Infect. 2021. PMID: 33592253 Free PMC article.
-
Diagnostic evaluation of Panbio™ antigen rapid diagnostic test for SARS-CoV-2: A systematic review and meta-analysis.J Virol Methods. 2023 Nov;321:114811. doi: 10.1016/j.jviromet.2023.114811. Epub 2023 Sep 9. J Virol Methods. 2023. PMID: 37696303
References
-
- World Health Organization . Coordinated global research roadmap: 2019 novel coronavirus. Geneva: WHO; (2020).
-
- Worldometer . COVID-19 coronavirus pandemic. (2021). Available at: https://wwwworldometersinfo/coronavirus/.
-
- World Health Organization . Antigen-detection in the diagnosis of SARS-CoV-2 infection. (2021). Available at: https://wwwwhoint/publications/i/item/antigen-detection-in-the-diagnosis....
LinkOut - more resources
Full Text Sources
Miscellaneous